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ABSTRACT
Microbiome studies show altered microbiota in head and neck squamous cell 
carcinoma (HNSCC), both in terms of taxonomic composition and metabolic capacity. 
These studies utilized a traditional bioinformatics methodology, which allows for 
accurate taxonomic assignment down to the genus level, but cannot accurately 
resolve species level membership. We applied Resphera Insight, a high-resolution 
methodology for 16S rRNA taxonomic assignment that is able to provide species-level 
context in its assignments of 16S rRNA next generation sequencing (NGS) data.
Resphera Insight applied to saliva samples from HNSCC patients and healthy 
controls led to the discovery that a subset of HNSCC saliva samples is significantly 
enriched with commensal species from the vaginal flora, including Lactobacillus 
gasseri/johnsonii (710x higher in saliva) and Lactobacillus vaginalis (52x higher 
in saliva). These species were not observed in normal saliva from Johns Hopkins 
patients, nor in 16S rRNA NGS saliva samples from the Human Microbiome Project 
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(HMP). Interestingly, both species were only observed in saliva from Human Papilloma 
Virus (HPV) positive and HPV negative oropharyngeal cancer patients. We confirmed 
the representation of both species in HMP data obtained from mid-vagina (n=128) 
and vaginal introitus (n=121) samples.
Resphera Insight also led to the discovery that Fusobacterium nucleatum, an oral 
cavity flora commensal bacterium linked to colon cancer, is enriched (600x higher) 
in saliva from a subset of HNSCC patients with advanced tumors stages.
Together, these high-resolution analyses on 583 samples suggest a possible role 
for bacterial species in the therapeutic outcome of HPV positive and HPV negative 
HNSCC patients.
INTRODUCTION
Microorganisms cause an estimated 20% of 
cancer in humans [1, 2]. The best-known example is the 
role Helicobater pylori plays in gastric cancer [3–5]. A 
handful of laboratories have reported links between the 
human microbiome, immuno modulators, inflammation 
and tumor initiation or progression in oral [6], colon 
[7–10], pancreatic [7, 11], liver [12], esophageal [13] and 
prostate cancers [14]. The biological mechanism of these 
associations is not yet understood [15, 16].
Cancer initiation, development, metastasis and its 
response to therapy are shaped by site specific genomic, 
epigenomic and immunologic alterations, all of which 
are related to acute or chronic inflammatory states, 
first described by Virchow 150 years ago [17, 18]. 
Four different types of inflammation seem to precede 
cancer initiation: 1) chronic inflammation associated 
to infections or autoimmune disorders; 2) low grade 
chronic inflammation associated to environmental 
irritants, health behaviors, or obesity; 3) tumor associated 
inflammation; 4) therapy-induced inflammation [19]. 
Cancer initiation and progression by oncogenic mutations, 
genomic instability, early tumor promotion, and enhanced 
angiogenesis are changes linked to chronic inflammation 
associated to multiple etiologies [20]. Tumor-associated 
inflammation enhances angiogenesis, promotes tumor 
progression and metastatic spread, and causes local 
immunosuppression [19]. Therapy-induced inflammation 
is linked to trauma, necrosis, and tissue injury, which 
stimulate tumor re-emergence and resistance to therapy 
[21, 22]. Conversely, therapy-induced inflammation can 
also enhance antigen presentation, leading to immune-
mediated tumor eradication [23].
The role of microbes and viruses in cancer 
development is also attributed to a wide spectrum of 
focalized changes driven by innate and adaptive immune 
responses [20]. There are several mechanisms by 
which bacterial infection can lead to the initiation and 
progression of oncogenic processes [2, 24, 25]. Most 
pathogen-induced tumors are preceded by pathogen, tissue 
and site specific host-mediated inflammatory states [26]. 
The normal tissue-repair response to injury and infection 
is orchestrated by an evolutionary conserved sequence 
of molecular changes triggered by pattern-recognition 
receptors (PRRs), many of which belong to the Toll-like 
receptor (TLR) family [27]. PPRs recognize pathogen 
associated molecular patterns (PAMPs) or damage 
associated molecular patterns (DAMPs) setting off a 
cascade of events that activate the innate immune response 
[27–30]. Bacterial endotoxins, metabolic byproducts of 
bacterial infection, and increased enzymatic activity as a 
result of bacterial infection, can induce somatic mutations 
and signaling pathway alterations [31].
Head neck squamous cell carcinomas (HNSCC) 
is a diverse group of tumor types, originally classified 
by anatomic subsite, but more recently best understood 
in terms of etiology, molecular drivers and immune 
phenotype [32, 33]. During the past twenty years the 
genomic and epigenomic changes in tumor development 
and treatment of HNSCC have been mapped [34–42]. 
These studies have revealed that the inactivation of the 
p53 and retinoblastoma (pRb) pathways are some of the 
earliest changes seen in both, HPV negative and HPV 
positive HNSSC patients. Inactivation of p53 and pRb 
in HPV negative tumors is due to the accumulation of 
somatic mutations and and/or promoter methylation 
events, while HPV positive tumors express the HPV 
oncoproteins E6 and E7, which also silence p53 and pRb 
[39, 41, 43, 44].
The method of excellence for performing initial 
microbiome characterization is sequencing the 16S rRNA 
gene to identify stable phylogenetic markers of taxonomic 
lineages for archaea and bacteria in a given sample [45, 
46]. The 16S rRNA gene has nine hypervariable regions, 
including a combination of variable and moderately 
conserved regions optimal for performing analyses 
at different phylogenetic depths. The V3-V5 region 
of the 16S rRNA gene is one of the preferred regions 
for characterizing the communities with few errors in 
taxonomic assignment [47–49].
Recently, we analyzed 16S rRNA amplicon 
sequencing data using a standard bioinformatics pipeline 
to unveil novel characteristics of the saliva microbiome 
from head and neck cancer patients treated for oral 
cancer, as well as for HPV positive and HPV negative 
oropharyngeal cancer [20]. Longitudinal analyses of 
samples taken before and after surgery, revealed a 
reduction in the alpha diversity measure after surgery, 
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together with an increase of this measure in patients that 
recurred (p<0.05). HNSCC patients had a significant loss 
in richness and diversity of microbiota species (p<0.05) 
compared to the controls. Overall, network analysis of 
operational taxonomic units (OTUs) demonstrated that the 
relative abundance of OTUs within genus Streptococcus, 
Dialister, and Veillonella could be used to discriminate 
HNSCC from control samples (p<0.05).
In this manuscript, we report the results of a novel 
analysis of this 16S rRNA dataset that allowed us to 
identify new associations between species in the saliva 
microbiome and tumor characteristics in the same HNSCC 
patient population treated in Johns Hopkins School of 
Medicine (JHU). We applied the Resphera Insight tool for 
high-resolution taxonomic assignment [50, 51], to perform 
a cross-sectional comparison at the species level of the 
microbial communities present in saliva DNA from HPV 
positive and HPV negative patients with cancer of the 
oropharynx, cancer of the oral cavity, and participants with 
normal oral cavity epithelium. We also selected between 
1-4 additional saliva samples collected in subsequent 
visits, from 10 of the 19 HNSCC patients to evaluate 
the longitudinal association between microbial species 
abundance and community members and treatment effects. 
We then confirmed the results obtained on the saliva 
samples from the JHU Discovery cohort on 514 samples 
from the Human Microbiome Project (HMP) [52].
RESULTS
Microbiome studies have revealed altered taxonomic 
composition in HNSCC saliva and tissue samples using a 
traditional bioinformatics methodology, which allows for 
accurate taxonomic assignment down to the genus level, 
but cannot accurately resolve species level membership. 
We applied Resphera Insight to classify bacterial species 
present in a quality-controlled set of clean 16S rRNA 
sequences previously analyzed by our group [20]. We 
first classified the species present in sequence datasets 
obtained with V3V5 region / Roche-454 FLX sequencing 
on 59 saliva DNA samples (17 HNSCC patients and 
25 normal controls; JHU Cohort). We then classified 
the species present in high-quality 16S rRNA sequence 
datasets obtained with V3V5 region / Roche-454 FLX 
sequencing on 514 samples from 154 unique participants 
in the Human Microbiome Project (Supplementary Tables 
1a and 1b): healthy human saliva (n=265), mid-vagina 
(n=128), and vaginal introitus (n=121) samples (Figure 1).
High-quality 16S rRNA sequences were analyzed 
with Resphera Insight, a high-resolution methodology for 
16S rRNA taxonomic assignment that is able to provide 
species-level context in its assignments (see Methods). 
A novel feature of the approach, when Resphera Insight 
is unable to make a confident single species assignment, 
the method will then provide an ambiguous assignment 
listing the specific set of species it cannot decide 
among. For example, an assignment of Lactobacillus_
gasseri:Lactobacillus_johnsonii could be narrowed to 
within these two species, but the method could not resolve 
the assignment further.
We found a total of 5 assigned phyla dominating 
across the samples: Firmicutes, Actinobacteria, 
Bacteroidetes, Fusobacteria, and Proteobacteria. 
(Supplementary Figure 1A). Overall, species-level 
profiles showed a dominance of Veilonella dispar across 
all samples (Supplementary Figure 1B). Streptococcus 
salivarius:Streptococcus vestibularis abundances were 
more dominant in HNSCC samples.
Hierarchical clustering of taxonomic profiles (top 
50 species level calls) shows that the salivary microbiome 
is distinct in HNSCC, with significant enrichment of 
Lactobacillus spp, Parvimonas micra, Streptococcus 
mutans, and Fusobacterium nucleatum (p < 0.05) in 
HNSCC samples and overall reduced alpha diversity 
(p < 1e-4) (Supplementary Figure 1C). We also found a 
larger percentage of Fusobacterium_nucleatum present 
in a subset of HNSCC saliva samples when compared 
with controls. Remarkably there is a highly significant 
depletion of Fusobacterium periodonticum, Leptotrichia 
trevisanii, Leptotrichia hofstadii, and Leptotrichia 
buccalis in HNSCC compared to controls in the JHU 
cohort (Supplementary Figure 2A- 2E). Fusobacterium_
nucleatum is closely related to each of these other species. 
Given these unexpected findings we decided to validate 
our results using publicly available saliva, vaginal introitus 
and mid-vagina samples from the Human Microbiome 
Project.
Principal coordinates analysis (PCoA) of the 
Bray-Curtis distances (β-diversity) show differences in 
community structure in saliva samples from HNSCC 
when compared to normal patients (Figure 2A). Principal 
coordinates analysis also demonstrated differences in 
community structure when comparing all 59 saliva 
samples from JHU patients with the 514 normal samples 
from the HMP, as expected (Figure 2B). Surprisingly, we 
observed clustering of HMP and JHU samples, which was 
unexpected because of the extremely strong processing 
signal present in microbiome samples. We found dense 
clustering between HMP saliva from normal participants 
and JHU control samples after performing PCoA on the 
combined JHU and HMP samples. Saliva samples from 
normal HMP and JHU cohorts clearly overlap in two of 
the four quadrants (Figure 2B). Similarly unexpected, 
a subset of JHU HNSCC samples cluster in the same 
quadrant as a subset of HMP mid-vagina and introitus 
samples, after PCoA was performed on the combined 
JHU and HMP samples. These results suggest that all 
normal and a subset of HNSCC samples from JHU, share 
components with samples from the HMP.
Microbial communities from control samples 
display significantly higher species richness (p<0.001) 
than HNSCC samples (Supplementary Figure 3A) 
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regardless of whether they are HPV positive or HPV 
negative samples (Supplementary Figure 3B). When 
examining Control and HNSCC samples with HMP saliva 
and vaginal samples, we found that Control and HMP 
saliva samples had the highest richness index followed by 
HNSCC and HMP vaginal samples (Supplementary Figure 
3C). No significant differences were observed (p=0.15) 
when comparing HPV positive and HPV negative HNSCC 
samples with JHU Control and HMP saliva and vaginal 
samples (Supplementary Figure 3D).
There were no differences in the microbial phyla 
present in the saliva control samples from JHU and saliva 
from participants in the HMP observed in the area plots 
of taxonomic summary for phyla (Supplementary Figure 
1A). Interestingly, at the species level (Supplementary 
Figure 1B) we found bacteria commonly seen in 
Figure 1: We utilized a quality-controlled set of clean sequences obtained by sequencing in a Roche-454 FLX the 
16S rRNA V3V5 region from 59 saliva DNA samples (17 HNSCC patients and 25 normal controls; JHU Cohort). 
Additionally, we obtained high-quality 16S rRNA sequence datasets obtained with V3V5 region / Roche-454 FLX sequencing on 514 
samples from 154 unique participants in the Human Microbiome Project.
Figure 2: Beta diversity comparisons by Principal Component Analysis (PCoA) discriminate: (A) Head and neck squamous cell carcinoma 
(n=17) from Control samples (n=25); (B) All 59 JHU saliva samples from three Human Microbiome Project datasets: saliva, mid vagina 
and introitus.
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the vaginal flora in saliva samples from a subset of 
Oropharyngeal Squamous Cell Carcinoma (OPSCC) 
patients. A subsequent analysis of the percentage 
of significant reads for these cohorts revealed that 
Fusobacterium nucleatum, an oral cavity flora commensal 
bacterium linked to colon cancer, is enriched (600x 
higher) in saliva from HNSCC patients (p < 0.05) (Figure 
3A). This analysis also uncovered that Lactobacillus_
rhamnosus, Lactobacillus_salivarius, Lactobacillus_
vaginalis; Lactobacillus_reuteri:Lactobacillus_vaginalis; 
Lactobacillus_fermentum, Lactobacillus_johnsoni, 
Lactobacillus_gasseri, and Lactobacillus_
gasseri:Lactobacillus_johnsonii were all enriched in a 
subset of HNSCC saliva samples from JHU, but not in 
normal saliva samples from JHU or saliva samples from the 
HMP. Most notably, Lactobacillus gasseri:Lactobacillus 
johnsonii was 710x higher in HNSCC and Lactobacillus 
vaginalis was 52x higher in HNSCC compared to controls 
(p<0.05). Lactobacillus_gasseri:Lactobacillus_johnsonii 
and Lactobacillus_gasseri were also present in vaginal 
introitus and mid-vagina samples from the HMP (p < 
0.05) (Figure 3B). We observed differences in abundance 
of significant Lactobacillus vaginalis and Lactobacillus_
gasseri:Lactobacillus_johnsonii reads in a subset of 
HPV positive and negative OPSCC (Supplementary 
Figure 4A). The relative enrichment is mostly seen in 
patients with larger tumors and nodal involvement (T3, 
N2) (Supplementary Figure 4B) and only in patients 
treated with multimodality therapy involving surgery and 
chemoradiation, when compared with patients only treated 
with surgical removal of the tumor (Supplementary 
Figure 4C).
The bacterial OTU network shown in Figure 4 
represents species that differed significantly in relative 
abundance (p<0.05) when comparing saliva from 
normal patients with patients with HNSCC, as well as 
HPV negative and HPV positive patients. Results for 
this algorithm shows various clustering in according 
to metadata for HNSCC, JHU Control Samples, HMP 
Saliva Samples, HMP mid-vaginal samples and vaginal 
introitus samples (Figure 4A). Pie charts were created 
showcasing taxa distinguishing JHU samples by histology 
and HMP by body compartment. Pie charts represent taxa 
that differed significantly in relative abundance (p<0.05) 
when comparing saliva from HNSCC patients (Figure 4B), 
JHU normal patients (Figure 4C), as well as HMP saliva 
samples (Figure 4D), HMP mid-vagina samples (Figure 
4E) and HMP vaginal samples (Figure 4F). The OTU 
Figure 3: (A) Frequency of significant reads for Streptococcus_mutans, Fusobacterium nucleatum, Parvimonas micra and Lactobacillus 
gasseri:johnsonnii (B) Relative abundance of significant 16S rRNA NGS reads for Lactobaccillus (p<0. 05), when comparing saliva from 
HNSCC patients with saliva from normal patients from Johns Hopkins saliva from normal participants in the Human Microbiome Project 
(HMP), as well as vaginal_introitus, and mid_vagina samples from participants in the HMP.
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network shows that the total abundance Lactobacillus 
gasseri/johnsonii, Haemophilus parainfluenza, 
Lactobacillus fermentum and Fusobacterium 
periodonticum can be used to discriminate HNSCC 
samples from control samples. Similarly, saliva samples 
from HNSCC patients, HMP mid-vaginal and vaginal 
introitus samples have a high abundance of Lactobacillus 
gasseri/johnsonii, commensal species of the vaginal flora.
We further examined the differential enrichment of 
bacterial OTUs in HNSCC saliva samples when compared 
to JHU saliva samples from normal patients. Sequencedata 
was log transformed and differential abundance plotted 
usingthe DESeq2 variance stabilization function available 
in Bioconductor. Single species significance tests (raw 
pvalue <0.05) were performed by one-way ANOVA. 
A single species heatmap using Euclidean distance 
to cluster 59 statistically significant JHU control and 
HNSCC samples’ OTUs (p<0.05) with the Hierarchical 
Unweighted Pair Group Method with Arithmetic 
Mean (UPGMA), shows that Streptococcus mutants, 
Lactobacillus fermentum and Lactobacillus rhamnosus 
are enriched in HNSCC samples (Supplementary Figure 
5A). A single species heatmap using Euclidean distance to 
cluster 573 statistically significant JHU and HMP samples’ 
OTUs (p<0.05) with the Hierarchical Unweighted Pair 
Group Method with Arithmetic Mean (UPGMA), shows 
that Streptococcus_salivarius: Streptococcus_vestibularis, 
Fusobacterium nucleatum, Prevotella oris, Rothia_
mucilaginosa, and Lactobacilus_gasseri:Lactobacillus_
johnsonii are enriched in HNSCC samples, when 
compared to normal saliva samples from JHU and HMP. 
We also observed a loss of enrichment of Prevotella_
jejuni:Prevotella melaninogenica, and Prevotella_pallens 
in HNSCC (Supplementary Figure 5B).
Figure 4: (A) Bacterial network of Operational Taxonomic Units at the species level that differed significantly in relative abundance (p<0. 
05), comparing saliva from normal patients from Johns Hopkins saliva from normal participants in the Human Microbiome Project (HMP), 
as well as vaginal_introitus, and mid_vagina samples from participants in the HMP. Pie charts representing taxa that differed significantly 
in relative abundance (p<0.05) when comparing (B) saliva from HNSCC patients, (C) JHU normal patients, (D) HMP saliva samples, (E) 
HMP Mid_Vagina and (F) HMP Vaginal_Introitus samples.
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Differentially enriched Lactobacillus species OTUs 
in HNSCC and JHU control samples were compared using 
the negative binomial Wald test for dispersion followed by 
variance stabilization. We found a significant association 
between Lactobacillus gasseri:johnsonii, Lactobacillus 
fermentum and Lactobacillus rhamnosus with HNSCC 
samples (p<0.0001). A single Lactobacillus OTU with 
multiple ambiguous Resphera assignments (multi species 
008) was more abundant in control samples (Figure 5).
We similarly compared significant (p<0.0001) 
differentially enriched Lactobacillus species OTUs 
in HNSCC and control samples from JHU and HMP 
saliva, mid-vagina and vaginal introitus from normal 
participants (Figure 6). This complex comparison shows 
that Lactobacillus_gasseri:Lactobacillus_johnsonii, 
Lactobacillus vaginalis, Lactobacillus fermentum, 
Lactobacillus salivarius and Lactobacillus rhamnosus 
were differentially enriched in 34 HNSCC samples when 
compared to 25 normal JHU saliva samples, as well as 290 
saliva samples and 249 vaginal samples from the HMP.
Differentially enriched Fusobacterium species 
OTUs in HNSCC and control samples were also compared 
using the negative binomial Wald test for dispersion 
followed by variance stabilization. (Supplementary 
Figure 6A). We found a significant enrichment of 
Fusobacterium nucleatum and Fusobacterium naviforme 
in a subset of HNSCC samples. Fusobacterium species, 
such as F. canifelium, F. nucleatum and F. naviforme 
were differentially abundant across all samples. We also 
compared differentially enriched Fusobacterium species 
OTUs between HNSCC samples and saliva controls 
from JHU and HMP saliva, mid-vagina and introitus 
(Supplementary Figure 6B). This complex comparison 
revealed an enrichment of Fusobacterium nucleatum and 
Fusobacterium naviforme with specific HNSCC samples.
We observed differences in abundance of significant 
Fusobacterium nucleatum reads in a subset of HNSCC 
in comparison to normal oral microbiota of HNSCC 
samples and saliva controls from JHU and HMP saliva 
(Supplementary Figure 6C), The relative enrichment of 
Fusobacterium_nucleatum in HNSCC saliva is mostly 
seen in patients with larger tumors and nodal involvement 
(T3, N2) (Supplementary Figure 6D) and only in patients 
treated with surgery and chemo-radio-therapy when 
compared with patients only treated with surgical removal 
of the tumor (Supplementary Figure 6E).
The relative enrichment of significant OTUs 
16S rRNA NGS reads of Fusobacterium_nucleatum, 
Lactobacillus_gasseri:Lactobacillus_johnsonii, and 
Lactobacillus gasseri in HNSCC saliva were compared 
by anatomic site (Supplementary Figure 7A), longitudinal 
sampling (Supplementary Figure 7B) and TNM stage 
(Supplementary Figure 7C). These three species are 
only concurrently seen in a subset of OPSCC patients: 
Figure 5: Heatmap differential abundance of significant (p<0.0001) Lactobacillus species’ OTUs in HNSCC when 
compared to JHU control samples with the variance stabilization method of QIIME’s 1.9.1 and DESeq2 normalization 
for data after logarithmic transformation, shows enrichment of Lactobacillus gasseri:johnsonnii, Lactobacillus 
fermentum and Lactobacillus rhamnosus with HNSCC samples. A single Lactobacillus OTU with multiple ambiguous Resphera 
assignments (multi species 008) was more abundant in control samples.
Oncotarget110938www.impactjournals.com/oncotarget
patients 5, 8, 10 and 13. Fusobacterium_nucleatum, and 
Lactobacillus_gasseri:Lactobacillus_johnsonii, were 
concurrently seen in more than half of the patients (8/17). 
The three species are only seen together in patients with 
larger tumors and nodal involvement (T2N2b or higher). 
We observed that Lactobacillus_gasseri:Lactobacillus_
johnsonii, and Fusobacterium_nucleatum can be present in 
both Oral Squamous Cell Carcinoma (OSCC) and OPSCC 
patients. We also observed that Lactobacillus_gasseri 
is only enriched in some OPSCC patients and always 
together with Lactobacillus_gasseri:Lactobacillus_
johnsonii enrichment. More importantly, the combined 
enrichment of Lactobacillus_gasseri:Lactobacillus_
johnsonii and Fusobacterium_nucleatum, is almost 
exclusively seen in larger lesions (T3) with nodal 
involvement (N2b and above). These patterns of relative 
enrichment occur in a background of Fusobacterium 
species presence, as shown by PCR amplification of 
Fusobacterium_spp in Supplementary Figures 7D-7F.
Longitudinal analyses of selected samples
We collected longitudinal post-treatment samples 
from a subset of 11 patients. We had two samples collected 
from six patients, three samples collected from three 
patients and four samples collected from four patients. The 
interval between sample collections ranged widely from 2 
to 99 weeks, with a mean of 25.4 weeks, a median of 16.5 
weeks and interquartile range of 25.4 weeks. Repeated 
samples were analyzed according to the type of treatment, 
HPV status and TNM staging based on relative abundance 
of OTUs. We found that community structure fluctuated 
by patient, but not significantly across all patients 
(Figure 7a). We did not observe significant longitudinal 
associations between community profiling and HPV status 
or TNM stage, probably due to small sample size and the 
wide range of intervals between repeated sampling. We 
did observe that while each patient had differentially 
abundant taxa between each time point, compared to each 
other overall, there was a decrease in Streptococcus as 
TNM stage progressed. Simultaneously, Lactobacillus_
salivarius, Lactobacillus_fermentum, Lactobacillus_
gasseri_johnsonii, and Lactobacillus_vaginalis’s OTUs 
increased in higher TNM stage categories across all 
patients (p<0.05) (Figure 7b).
DISCUSSION
This is the first analysis of 16S rRNA NGS data 
that identifies commensal species from the vaginal 
flora, Lactobacillus gasseri/johnsonii and Lactobacillus 
vaginalis, in saliva from HPV positive and HPV negative 
oropharyngeal cancer patients. These commensal 
vaginal species were not observed in the combined 290 
saliva samples of normal participants from the JHU 
Figure 6: Heatmap differential abundance of significant (p<0.0001) Lactobacillus species’ OTUs in HNSCC when 
compared to JHU control samples and saliva, mid_vagina and vaginal_introitus samples from normal HMP participants 
with the variance stabilization method of QIIME’s 1.9.1 and DESeq2 normalization for data after logarithmic 
transformation, shows differential enrichment of Lactobacillus_gasseri:Lactobacillus_johnsonnii, Lactobacillus vaginalis, 
Lactobacillus fermentum, Lactobacillus salivarius and Lactobacillus rhamnosus in 34 HNSCC samples when compared to 
25 normal JHU saliva samples, as well as 290 saliva samples and 249 vaginal samples from the HMP.
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and HMP cohorts. This study is also the first to identify 
Fusobacterium nucleatum, an oral cavity flora commensal 
bacterium linked to colon cancer, enriched in saliva from 
a subset of HNSCC patients with advanced tumors, when 
compared with controls. These unexpected results were 
confirmed using high-resolution microbiome profiling to 
the species level, of NGS data from a total of 583 clinical 
and HMP control samples from the oral and vaginal flora.
We found a significant presence of Lactobacillus 
OTUs from several different species in tumor 
when compared to control samples: Lactobacillus_
gasseri:Lactobacillus_johnsonii, Lactobacillus vaginalis, 
Figure 7: (A) Time-series analyses of HNSCC patients (n=11) for whom we had repeated saliva samples, according to both sampling sites, 
HPV status and TNM staging. The interval between sample collections ranged widely from 2 to 99 weeks, with a mean of 25.4 weeks, a 
median of 16.5 weeks and interquartile range of 25.4 weeks. Repeated samples were analyzed according to the type of treatment, HPV status 
and TNM staging based on relative abundance of OTUs. We found that community structure fluctuated by patient, but not significantly 
across all patients. (B) Relative abundance of Lactobacillus and Fusobacterium species in HNSCC patients (n=11) for whom we had 
repeated saliva samples, according to both sampling sites, HPV status and TNM staging. Bacterial communities were noticeably different 
between T1-2N2AM0 or lower and T3N2BM0 or higher TNM stage. While each patient had differentially abundant taxa between each 
time point, compared to each other overall, there was a decrease in Streptococcus as TNM stage progressed. Simultaneously, Lactobacillus_
salivarius, Lactobacillus_fermentum, Lactobacillus_gasseri_johnsonii, and Lactobacillus_vaginalis’s OTUs increased in higher TNM stage 
categories across all patients (p<0.05).
A
B
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Lactobacillus fermentum, Lactobacillus salivarius 
and Lactobacillus rhamnosus. Subset analyses of 
the longitudinal samples revealed that the abundance 
of Lactobacillus_gasseri:Lactobacillus_johnsonii, 
Lactobacillus fermentum, Lactobacillus salivarius and 
Lactobacillus rhamnosus was higher in oropharyngeal 
cancer patients. We also found increased abundance of 
Lactobacillus species with advanced T and N stages, in 
patients from whom we had collected saliva samples at 
different time points.
These results expand to the species level the 
findings of our prior report, which for the first time 
detected Lactobacillus in saliva from HNSCC patients 
[53]. As expected, the high-resolution microbiome 
profiling tools used in this report identified the presence 
of the same phyla we observed in our previous report: 
Firmicutes, Actinobacteria, Bacteroidetes, Fusobacteria, 
and Proteobacteria. Another group recently reported 
that Actinomyces, and its parent taxa up to the phylum 
level, were significantly depleted in HNSCC tumor tissue 
when compared to adjacent normal tissue [54]. They 
also reported that, Parvimonas was increased in HNSCC 
relative to normal tissue; Actinobacteria is differentially 
enriched in oral and oropharyngeal cancer tissue samples 
when compared to nasopharyngeal and larynx tissue 
samples; and that these differences were more pronounced 
among patients with more extensive disease, as measured 
by higher T-stage [54]. This same group also previously 
reported an association between microbiomic profiles and 
MDR1 methylation in tissues from HNSCC patients when 
compared to normal tissues [55]. None of these reports 
discussed the presence of Lactobacillus in HNSCC tissue 
samples.
Lactobacillus has been associated with caries, 
hyposalivation or xerostomia, and has been observed 
in deep dentinal caries associated with pulpitis in 
adults [56]. However, their role is mainly protective. 
Lactobacilli inhibit binding of other bacteria to epithelial 
cells and produce lactic acid that kills or inhibits the 
growth of many other bacteria. Lactic acid blocks histone 
deacetylases, thereby enhancing gene transcription and 
DNA repair. Lactic acid induces autophagy in epithelial 
cells to degrade intracellular microorganisms and promote 
homeostasis [57].
For many decades, lactobacilli have been used as 
an effective probiotic therapy against several pathological 
conditions. in vitro and in vivo studies show that prolonged 
lactobacilli administration induces qualitative and 
quantitative modifications in the human gastrointestinal 
microbial ecosystem, with concurrent physiological and 
immunological changes that lead to improvement of 
different pathological conditions [58, 59].
Lactobacilli are the most abundant vaginal bacteria 
in women where they play a protective role. Lactobacilli 
are tolerated by vaginal epithelial cells and inhibit 
induction of pro-inflammatory cytokines. The normal 
microbial flora of the vagina plays an important role in 
preventing genital and urinary tract infections in women. 
The association between the vaginal microbiome and 
bacterial vaginosis (BV), an imbalance of the vaginal 
bacterial microbiota of unknown etiology, has been 
studied with different methods. Studies of the vaginal 
flora using NGS, 454-pyrosequencing, PCR and microbial 
isolation methods have yielded inconsistent results [60]. 
The prevalence of Lactobacillus crispatus, Lactobacillus 
jensenii, and Lactobacillus gasseri is significantly higher 
in the vaginal flora of healthy women when compared to 
women with BV [61]. The vaginal flora in women with 
BV changes from a Lactobacillus-dominant vaginal 
microbiota to an anaerobic and facultative bacterial 
dominance. It is only in those women with a BV diagnosis 
in which the identified bacteria are atypical and persist 
that BV may be a clinical problem requiring intervention 
[62]. Analysis of the bacterial communities by 16S rRNA 
amplicon sequencing revealed two clusters in the BV 
negative women, dominated by either Lactobacillus iners 
or Lactobacillus crispatus and three distinct clusters in the 
BV positive women. BV positive subjects showed cluster 
profiles that were relatively high in bacterial species 
diversity and dominated by anaerobic species, including 
Gardnerella vaginalis, and those belonging to the Families 
of Lachnospiraceae and Leptotrichiaceae [63].
The normal microbial flora of the vagina also seems 
to differ across race and cultural divides. Black women 
are more likely to be colonized by L. iners than the other 
Lactobacillus species. In contrast, healthy women of 
European ancestry are more likely to be colonized with 
three health-associated Lactobacillus species, namely 
L. crispatus, L. jensenii and L. gasseri, and exhibited 
significantly lower bacterial diversity. Lactobacillus 
gasseri was found to be negatively associated with 
BV in Chinese women [64]. Lactobacillus johnsonii, 
Lactobacillus gasseri and Lactobacillus vaginalis strains 
have been isolated from women in Brazil with or without 
BV, with an intermediate frequency in the two groups [65].
Together these data suggest that the presence 
of Lactobacillus gasseri/johnsonii and Lactobacillus 
vaginalis in saliva from oropharyngeal patients may be 
due to the transmission of commensal bacterial from 
normal vaginal to the oral flora during oral sex. If this 
finding is validated in other cohorts, potential interactions 
between Lactobacillus gasseri/johnsonii and Lactobacillus 
vaginalis in saliva with the persistence and eventual 
carcinogenesis of high risk HPV types in oropharyngeal 
cancer should be explored. Their role in the apparent 
difference in oropharyngeal cancer rates between Black 
and Non-Latino White men should also be explored.
This study is also the first to identify Fusobacterium 
nucleatum enriched in a subset of saliva samples 
from HNSCC patients, when compared with controls. 
Interestingly, we also observed a highly significant 
depletion of bacterial species closely related to 
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Fusobacterium nucleatum in saliva from in HNSCC 
patients. Fusobacterium periodonticum, Leptotrichia 
trevisanii, Leptotrichia hofstadii, and Leptotrichia buccalis 
are enriched in saliva control samples from the JHU and 
HMP cohorts. Our PCR results for Fusobacterium_spp 
suggest a ubiquitous presence of the Fusobacterium 
family in HNSCC.
Fusobacterium nucleatum is one of the whole 
Fusobacterium species (Pan-fusobacterium) that are 
abundant in colorectal carcinoma (CRC) tissue compared 
with adjacent normal mucosa [66, 67]. Fusobacterium 
enrichment is associated with a subset of tumors 
that exhibit well-characterized molecular hallmarks 
of CRC: CpG island methylator phenotype (CIMP), 
Microsatellite Instability (MSI), hMLH1 methylation 
positivity and high mutation burden [68]. It is not clear 
if Fusobacterium nucleatum is a driver of tumorigenesis 
or a well- positioned passenger. A potential oncogenic 
mechanism has been proposed: Fusobacterium nucleatum 
may promote colorectal carcinogenesis by modulating 
E-cadherin/β-catenin signaling via its FadA adhesion 
molecule. FadA binds to E-cadherin, activates β-catenin 
signaling, and differentially regulates inflammatory and 
oncogenic responses [69]. Binding of FadA to E-cadherin 
on the cell surface mediates attachment and invasion of 
Fusobacterium nucleatum into CRC epithelial cells, 
inhibiting their tumor-suppressor activity and activating 
b-catenin signaling. Fusobacterium nucleatum then 
invades the cell via internalization of E-cadherin by 
Clathrin and stimulates expression of inflammatory genes 
[70]. As a result, b-catenin phosphorylation is decreased, 
resulting in increased b-catenin in the cytoplasm and 
translocation into the nucleus where it modulates 
increased expression of LEF, TCF, NF-kb, and other 
oncogenes. On the other hand, Fusobacterium nucleatum 
does not exacerbate colitis, enteritis, or inflammation- 
associated intestinal carcinogenesis, which is contrary 
to the role of other colon cancer-associated bacteria 
[71]. Fusobacterium nucleatum alone may not be a 
driver of colorectal tumorigenesis, but may contribute 
to the development of colorectal cancer by synergistic 
associations with other bacteria or even possibly with 
fungi and viruses [72]. Together, the data suggest that 
Fusobacterium nucleatum may generate, in a subset of 
patients, a proinflammatory microenvironment through 
recruitment of tumor-infiltrating immune cells that is 
conducive for colorectal neoplasia progression.
The microbiome of the oral cavity is the second 
most diverse one of the human body after the gut [52]. The 
oral microbiome, which can cause both oral and systemic 
disease, grows in an ecosystem of biofilms throughout the 
oral cavity, existing in a balanced immunoinflammatory 
state with the host that maintains health when in 
equilibrium [73]. However, certain species, such as 
Porphyromonas gingivalis, can disrupt this equilibrium, 
resulting in dysbiotic host-microbiota interactions [74]. 
Fusobacterium nucleatum is considered to be a key 
oral bacterium in recruiting periodontal pathogens into 
subgingival dental plaque [75].
There is emerging evidence of associations between 
malignant oral lesions with chronic periodontitis, as well 
as chronic abundance of Porphyromonas gingivalis, and 
Fusobacterium nucleatum, among other microbes [76]. 
OSCC surfaces have been reported to harbor significantly 
higher levels of Porphyromonas and Fusobacterium 
compared with contiguous healthy mucosa [77]. However, 
a causal role for oral microbiota in OSCC or OPSCC is 
just beginning to be delineated. Porphyromonas gingivalis 
induces the expression of the B7-H1 and B7-DC receptors 
in primary OSCC cells, which are upregulated in a variety 
of cancers and contribute to chronic inflammation [78]. 
Chronic infection with Porphyromonas gingivalis and 
Fusobacterium nucleatum has been recently shown 
to promote tongue tumors in a murine model via 
direct interaction with oral epithelial cells, leading to 
upregulation of the IL-6-STAT3 pathway in a TLR2-
dependent manner [79].
The oral microbiome metabolism is not well 
studied [80]. Early studies suggest that that the main 
carbon metabolic pathways, such as the Embden-
Meyerhof-Parnas (EMP) pathway, the pentose phosphate 
(PP) pathway, and the tri-carbonic acid (TCA) cycle, as 
well as amino acid metabolism-related pathways, are in 
operation in the oral biofilm in vivo and exhibit similar 
characteristics to those of Streptococcus and Actinomyces 
[81, 82]. Dysregulation of these main carbon metabolic 
pathways have been correlated to dental caries, periodontal 
disease and oral cancer in small studies [83–85]. The 
following five saliva metabolomic biomarkers can 
discriminate from early HNSCC patients from controls: 
propionylcholine, N-Acetyl-L-phenylalanine, sphinganine, 
phytosphingosine, and S-carboxymethyl-L-cysteine [86]. 
Their association to members of the saliva microbiome 
has not been studied. There is contradictory metabolomics 
evidence supporting the pathogenic role of Fusobacterium 
nucleatum in the oral cavity. Some studies have observed 
that Fusobacterium nucleatum upregulates the expression 
of lysine degradation pathway leading to butyrate 
production in periodontitis patients [87]. However, the 
routes of butyrate production may differ by Fusobacteria 
strain or substrains [88]. Fusobacterium nucleatum can 
be subdivided into five subspecies. Virulence genes in the 
W1481 subspecies genome may provide a strong defense 
mechanism that might enable it to colonize and survive 
within the host by evading immune surveillance [89].
Further studies are needed to determine the role of 
Lactobacillus gasseri/johnsonii, Lactobacillus vaginalis 
and Fusobacterium nucleatum in OPSCC and OSCC 
pathogenesis in diverse populations and their possible uses 
for screening, diagnostic and chemoprevention strategies 
with probiotic therapy. Gut microbiome has been 
associated with response to immune checkpoint blockade 
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[90]. While immune checkpoint inhibitors are emerging 
as a promising treatment modality for HNSCC [91], the 
oral microbiome should be investigated for potential 
interactions with immune therapy.
MATERIALS AND METHODS
Johns Hopkins Hospitals cohort
The Discovery cohort patients selected for this 
study were nested within a longitudinal cohort study of 
787 patients who presented with histopathologically 
confirmed HSNCC (this includes patients who presented 
for treatment of a recurrence after primary treatment at 
an outside hospital) to the outpatient clinic of the Johns 
Hopkins Hospital in Baltimore, Maryland from 2000 to 
2011. Patients were included if they had at least one pre-
treatment salivary sample and consented for the study. 
All patients had undergone treatment with curative intent. 
Patients were consented for this study under the molecular 
surveillance clinical research protocol. The study 
protocol was approved by the institutional review board 
of the Johns Hopkins Hospital, as well as by the JHU 
Institutional Review Board. Written informed consent 
was obtained from all patients. Once consented, patients 
are tracked by our patient coordinators, who working in 
tandem with our surgeons, use the same sample collection 
and processing protocol that have historically been used 
in the Head and Neck Cancer Tumor Bank (HAND) to 
collect and process samples.
Samples were collected between 2000 and 2011 
and stored in the JHU Head and Neck Cancer Research 
Division’s Tumor Bank, from where they were randomly 
selected for this study. Saliva was collected from 44 
patients: 25 patients with no history of cancer and 19 
HNSCC patients. Longitudinal saliva samples were 
collected from 58% of the HNSCC patients, totaling 62 
samples. None of the patients were treated with antibiotics 
during a six-month period prior to sample collection. We 
eliminated 3 samples from 2 patients (2 OSCC and 1 
OPSCC), 2 of them with unknown HPV status, as well as 
an HPV positive OSCC saliva sample.
The analyses presented here are based on a total of 
59 saliva samples acquired from 42 patients; of these, 34 
saliva samples corresponded to 17 HNSCC patients and 
25 saliva samples corresponded to 25 controls without 
cancer, which also had negative smoking and drinking 
histories. Most of the HNSCC patients were OPSCC 
(58%). There was no difference in median age (66 and 
62 years) or percentage of male patients (67% and 77%) 
between OSCC and OPSCC patients. Forty-seven percent 
(47%) of the HNSCC, all of them OPSCC patients, were 
HPV positive. Most OPSCC patients (64%) were HPV 
positive. Most HNSCC patients were former smokers 
or never smokers: OPSCC (72%) and OSCC (63%). 
Similarly, most HNSCC patients were occasional drinkers 
or non-drinkers: OPSCC (72%) and OSCC (63%). 
Approximately half of the patients were diagnosed with 
T1 or T2 stage tumors: OSCC (50%) and OPSCC (55%). 
Most patients had nodal involvement: OSCC (75%) 
and OPSCC (73%). None of the patients had known 
metastasis. All the OPSCC were treated with surgery and 
chemoradiation, compared to only 25% of the OSCC. 
Most of the OSCC patients (63%) only required surgical 
treatment (Supplementary Table 2). Ten patients provided 
between 1 to 3 longitudinal, post-treatment samples. The 
age of these patients ranged from 43 to 67 years of age, 
with a median 61 years. Most patients were males (80%), 
OPSCC (80%), T1-T2 stage (70%), non-smokers (70%), 
treated with surgery, followed by chemo-radiation (70%) 
treatment (Supplementary Table 3).
Human microbiome project cohort
We obtained quality-controlled 16S rRNA sequence 
datasets from the Human Microbiome Project Data 
Analysis and Coordination Center (HMPDACC; public-
ftp.hmpdacc.org [52, 92]), generated by sequencing of the 
16S rRNA V3–V5 hypervariable region on the Roche-454 
FLX Titanium instrument for a total of 537 saliva, mid-
vagina, and vaginal introitus samples. In total, 514 of the 
537 HMP samples (96%) downloaded for this project had 
at least 2,500 high-quality V3V5 sequences (≥ 200bp) and 
were subsequently used for downstream analysis including 
healthy human saliva (n=265), mid-vagina (n=128), and 
vaginal introitus (n=121) samples. These 514 samples 
were obtained from 154 unique participants: saliva 
(n=154), mid-vagina (n=79), and vaginal introitus (n=73), 
most of whom provided two longitudinal samples.
DNA extraction
Microdissected tissues and saliva (2mL) samples 
were centrifuged and the pellets were digested with 1% 
SDS and 50 μg/mL proteinase K (Boehringer, Mannheim, 
Germany) at 48°C overnight extracted with phenol/
chloroform, precipitated in 100% ethanol, centrifuged at 
5100 rpm for 45 minutes, washed in 70% ethanol twice, 
dissolved in LoTE buffer (10mM TRIS hydrochloride, 
1mM EDTA buffer, pH 8), and stored at −20°C [93].
Creation of the 16S rRNA V3-V5 amplicon 
library
An amplicon library from individual samples was 
created by PCR amplification with unique barcoded 
primers of the 16S rRNA V3-V5 gene region, using 
the 357F/926R primer set. We used 14 different 
barcode sequences and the linker primer sequence 
CCGTCAATTCMTTTRAGT to analyze the 16S rRNA 
V3–V5 hypervariable 16S rRNA gene region.
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DNA sequencing and bioinformatics analyses
Sequencing of the multiplexed amplified 
fragments was performed on the Roche/454 GS Junior 
pyrosequencing platform. Bioinformatics preprocessing 
steps included quality filtering, error-correction, and 
chimera removal. Briefly, reads were de-multiplexed 
using 5’ barcodes, trimmed of forward and reverse primer 
sequences, filtered for length and quality, and corrected 
for homopolymer errors. High quality reads were selected 
for analysis and reads with unknown bases (“N”) were 
discarded.
Sequences underwent strict quality and size 
filtering, removing reads shorter than 150bp, as well as 
those with mismatches and poor quality scores. Sequences 
were then error-corrected using the Acacia tool, followed 
by de novo chimera detection with the UCHIME program, 
and screening for chloroplast contaminant sequences, as 
previously described [53].
High-quality 16S rRNA amplicon sequences 
passing preprocessing were submitted to Resphera 
Insight (Baltimore, MD, www.respherabio.com) for high-
resolution taxonomic identification of bacterial species 
[50, 51, 94–96]. The Insight methodology relies on a 
manually curated 16S rRNA database with over 11,000 
bacterial species and a hybrid global-local alignment 
strategy to provide accurate species-level context for 16S 
rRNA microbiome profiling studies.
After considering the raw count data in full above, 
subsample analysis of each community was performed 
to an equivalent depth, in this case, 3,400 sequences per 
sample for the comparisons between HNSCC and control 
saliva data. When comparisons were done with HPM 
datasets, we used 2,500 sequences per sample to avoid 
eliminating samples for analyses. All results are therefore 
based on the subsampled data, which mitigates biases due 
to differences in sampling depth.
An OTU network was generated using QIIME 
[97] and imported to Cytoscape [98] based on OTUs that 
changed significantly in abundance (p<0.05) as result of 
a maximum likelihood statistical significance tests. The 
selected OTUs were plotted choosing nodes from the OTU 
network and sorting edges interaction by the four different 
sample types: normal, HPV negative OSCC, HPV 
negative OPSCC and HPV positive OPSCC. Additionally, 
we represented the taxonomy of taxa at the genus-level 
through pie charts at each of the four sample types.
Quantitative PCR
The 7900HT real time PCR system was used 
to perform quantitative PCR for HPV-16 E6 and E7 
and B-actin. Specific primers and probes have been 
designed to amplify the E6 and E7 regions of HPV 
type 16: HPV-16 E6 forward primer, 5’-TCAGGACCC 
ACAGGAGCG-3’; HPV-16 E6 reverse primer, 
5’-CCTCACGTCGCAGTAACTGTTG-3’, HPV-16 E6  
TaqMan probe, 5’-(FAM)-CCCAGAAAGTTACCAC 
AGTTATGCACAGAGCT-(TAMRA)-3’, HPV-16 E7 
forward primer, 5’-CCGGACAGAGCCCATTACAA-3’, 
HPV-16 E7 reverse primer, 5’-CGAATGTCTACG 
TGTGTGCTTTG-3’, HPV-16 E7 TaqMan probe, 
5’-(FAM)-CGCACAACCGAAGCGTAGAGTCACACT-
(TAMRA)-3’. A housekeeping gene (B-actin) were 
run in parallel with HPV-16 E6 and E7 to standardize 
the input DNA: B-actin forward primer, 5’-TCACC
CACACTGTGCCCATCTACGA-3’, B-actin reverse 
primer, 5’-CAGCGGAACCGCTCATTGCCAATGG-3’, 
B-actin TaqMan probe, 5’-(FAM)-ATGCCCTCCCCCAT 
GCCATCCTGCGT-(TAMRA)-3’. The 7900HT real time 
PCR system was also used to perform quantitative PCR 
for Fusobacterium_spp. and B-actin. We used previously 
designed primers and probes to amplify Fusobacterium_
spp [99]: Fusobacterium_spp forward primer, 5’- 
GGATTTATTGGGCGTAAAGC -3’; Fusobacterium_spp 
reverse primer, 5’- GGCATTCCTACAAATATCTACGAA 
-3’; Fusobacterium_spp TaqMan probe, 5’-(FAM)- 
CTCTACACTTGTAGTTCCG -(TAMRA)-3’.
All samples were run in triplicate. The CaSki 
(American Type Culture Collection, Manassas, VA) cell 
line was used to develop standard curves for the HPV 
viral copy number as it is known to have 600 copies/
genome equivalent. Standard curves for HPV-16 E6 and 
E7 were developed by using DNA extracted from CaSki 
cells, serially diluted into 50 ng, 5 ng, 0.5 ng, 0.05 ng, 
and 0.005 ng. A standard curve was also developed for the 
housekeeping gene B-actin (2 copies/genome), using the 
same serial dilutions of CaSki DNA. Saliva samples with 
> 0 copy/genome were considered as HPV positive. No 
statistical correlation was attempted due to modest sample 
size.
Statistical analysis
For each group comparison, significance tests were 
computed including the maximum likelihood statistical 
significance tests that determine whether OTU presence/
absence is associated with a category in the metadata. 
QIIME [97] was used to run the R interface package of 
DESeq2 for the negative binomial Wald test and Variance 
Stabilizing Transformations. These procedures diminish 
the large variation between count data across diverse 
samples providing a robust method of comparison between 
samples. Reported fold changes for specific species reflect 
the ratio of mean relative abundance in cancer patients 
to the mean of controls. The relative group variance 
homogeneity was verified with the function ‘betadisper’ 
also in the “vegan” package. Richness box and whisker 
plots were calculated using both vegan [100] and Phyloseq 
[101] R packages.
QIIME was also used to generate clustering with 
heatmaps and estimate alpha-diversity metrics including 
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raw number of OTUs per sample, Chao1 estimator, 
Shannon entropy, Non-Metric dimensional scaling, and 
Bray-Curtis distance metric. To better understand the 
bacterial OTU diversity in our cohorts, we compared the 
alpha rarefaction curves between normal and HNSCC 
samples according to the Chao 1 richness estimator. 
The Chao1 index estimates total species richness based 
on all species actually discovered, including species not 
present in any sample. This approach uses the numbers 
of singletons (single appearance) and doubletons (that 
appeared twice) to estimate the number of missing species 
due to undetected species information on low frequency 
counts.
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